Loading...
Severe Delayed-Onset Neutropenia Induced by Ocrelizumab
BACKGROUND: Ocrelizumab is an anti-CD20 monoclonal antibody that has been shown to reduce disability progression in primary progressive multiple sclerosis (MS). The adverse event profile is still being determined through postmarketing surveillance and case reports. OBJECTIVE: To report a case of sev...
Na minha lista:
| Udgivet i: | Neurohospitalist |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8022193/ https://ncbi.nlm.nih.gov/pubmed/33868559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1941874420936438 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|